U.S. Markets closed

Catabasis Pharmaceuticals, Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Showing Early Clinical Success

NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Catabasis Pharmaceuticals, Inc. (CATB), is a clinical-stage biopharmaceutical company. The company's lead program in development is edasalonexent for the treatment of Duchenne muscular dystrophy.

The company will present data from the MoveDMD® trial of edasalonexent (CAT-1004) at the New Directions in Biology and Disease of Skeletal Muscle Conference, the 2018 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference and the 15thInternational Congress on Neuromuscular Diseases. New Directions in Biology and Disease of Skeletal Muscle Conference is to be held between June 25 - June 28, 2018, in New Orleans.

Read about the next clinical move for edasalonexent and Catabasis Pipeline review READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/catabasis-pharmaceuticals/

As evidenced by sustained improvements in all assessments of physical function and in biomarkers of muscle health and inflammation, edasalonexent has slowed the progression of Duchenne in the MoveDMD trial. The company believes that these effects ultimately will translate to boys with Duchenne maintaining functional abilities longer and as per management company resources have been aligned to focus on its lead program edasalonexent for the treatment of DMD.

Get details of the Q1 financial review and key investment highlights READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/catabasis-pharmaceuticals/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source